Lin Gang, Lou Yue
Department of Orthopedics, Children's Hospital of Nanjing Medical University, Nanjing 210000, People's Republic of China.
Indian J Cancer. 2017 Jul-Sep;54(3):580-583. doi: 10.4103/ijc.IJC_297_17.
Numerous studies have investigated the role of p16 alteration in patients with soft tissue sarcomas (STSs) yielding inconsistent and inconclusive results. Hence, we conducted a meta-analysis to precisely assess its prognostic value.
Electronic literature databases such as PubMed, EMBASE, Web of Science were searched, and five studies with a total of 536 patients were eligible for this meta-analysis. Pooled hazard ratio (HR) with 95% confidence interval (95% CI) of overall survival (OS) was used to assess the prognostic role of p16 alteration.
Overall, the pooled HR for all five eligible studies evaluating decreased p16 expression on OS was 1.47 (95% CI: 1.14-1.90); sensitivity analysis suggested that the pooled HR was stable and omitting a single study did not change the significance of the pooled HR. There is no evidence of publication bias in the meta-analysis.
In conclusion, this meta-analysis showed that decreased p16 expression is associated with lower OS rate in patients with STS, and it is an effective biomarker of prognosis.
众多研究探讨了p16改变在软组织肉瘤（STS）患者中的作用，但结果不一致且尚无定论。因此，我们进行了一项荟萃分析以准确评估其预后价值。
检索了PubMed、EMBASE、Web of Science等电子文献数据库，五项研究共536例患者符合本荟萃分析的条件。采用总生存（OS）的合并风险比（HR）及95%置信区间（95%CI）来评估p16改变的预后作用。
总体而言，五项评估p16表达降低对OS影响的合格研究的合并HR为1.47（95%CI：1.14 - 1.90）；敏感性分析表明合并HR稳定，剔除任何一项研究均不改变合并HR的显著性。荟萃分析中无发表偏倚的证据。
总之，本荟萃分析表明p16表达降低与STS患者较低的OS率相关，它是一种有效的预后生物标志物。
